During the past decade, Handok Pharmaceuticals conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Handok Pharmaceuticals" are "Type 2 Diabetes Mellitus" (2 trials) and "Asthma" (1 trials). Many other conditions were trialed in "Handok Pharmaceuticals" in a lesser frequency.

Most popular intervention types in "Handok Pharmaceuticals" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Glimepiride/ Metformin" (1 trials), "metformin 1500mg plus metformin 500mg or 1000mg (Diabex)" (1 trials) and "vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Handok Pharmaceuticals" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Handok Pharmaceuticals". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Handok Pharmaceuticals, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Handok Pharmaceuticals, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".